The remarkable conformational plasticity of alpha-synuclein: blessing or curse?

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Trends in Molecular Medicine

• Publication date

  2013-06-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.molmed.2013.04.002PMID 23648364
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Alpha‐synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease

  2013cited by this paper
• 100 years of Lewy pathology

  2013cited by this paper
• In Vivo Cross-linking Reveals Principally Oligomeric Forms of α-Synuclein and β-Synuclein in Neurons and Non-neural Cells*

  2013cited by this paper
• α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson’s disease and multiple system atrophy?

  2013cited by this paper
• Prion-like spreading of pathological α-synuclein in brain

  2013cited by this paper
• Alpha-Synuclein Posttranslational Modification and Alternative Splicing as a Trigger for Neurodegeneration

  2012cited by this paper
• Chemical and semisynthesis of posttranslationally modified proteins.

  2012cited by this paper
• Α-synuclein misfolding and Parkinson's disease.

  2012cited by this paper
• Vaccination for Parkinson's disease.

  2012cited by this paper
• Paraquat, but Not Maneb, Induces Synucleinopathy and Tauopathy in Striata of Mice through Inhibition of Proteasomal and Autophagic Pathways

  2012cited by this paper
• Direct Observation of the Interconversion of Normal and Toxic Forms of α-Synuclein

  2012cited by this paper
• Targeting phosphatases as the next generation of disease modifying therapeutics for Parkinson's disease.

  2012cited by this paper
• Chemical and Semisynthesis of Posttranslationally Modified Proteins

  2012cited by this paper
• Pathological α-Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Nontransgenic Mice

  2012cited by this paper
• Bacterial in-cell NMR of human α-synuclein: a disordered monomer by nature?

  2012cited by this paper
• Monomeric Synucleins Generate Membrane Curvature*

  2012cited by this paper
• Positive Lysosomal Modulation As a Unique Strategy to Treat Age-Related Protein Accumulation Diseases

  2012cited by this paper
• Elucidating the role of C-terminal post-translational modifications using protein semisynthesis strategies: α-synuclein phosphorylation at tyrosine 125.

  2012cited by this paper
• Chelators in the Treatment of Iron Accumulation in Parkinson's Disease

  2012cited by this paper
• Rational design of potent domain antibody inhibitors of amyloid fibril assembly

  2012cited by this paper
• Use of viral vectors to create animal models for Parkinson's disease.

  2012cited by this paper
• Spinal cord lesions in sporadic Parkinson’s disease

  2012cited by this paper
• Two different binding modes of α-synuclein to lipid vesicles depending on its aggregation state.

  2012cited by this paper
• Industrial toxicants and Parkinson's disease.

  2012cited by this paper
• Folding and misfolding of alpha-synuclein on membranes.

  2012cited by this paper
• Meta-Analysis of Early Nonmotor Features and Risk Factors for Parkinson Disease

  2012cited by this paper
• α-Synuclein in Central Nervous System and from Erythrocytes, Mammalian Cells, and Escherichia coli Exists Predominantly as Disordered Monomer*

  2012cited by this paper
• Elucidating the role of post-translational modifications of alpha-synuclein using semisynthesis

  2012cited by this paper
• Genetically engineered mouse models of Parkinson's disease.

  2012cited by this paper
• Systematic Mutagenesis of α-Synuclein Reveals Distinct Sequence Requirements for Physiological and Pathological Activities

  2012cited by this paper
• α-Synuclein phosphorylation as a therapeutic target in Parkinson’s disease

  2012cited by this paper
• Exosomal cell-to-cell transmission of alpha synuclein oligomers

  2012cited by this paper
• A soluble α-synuclein construct forms a dynamic tetramer

  2011cited by this paper
• α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells.

  2011cited by this paper
• In vivo demonstration that α-synuclein oligomers are toxic

  2011cited by this paper
• Structure-based design of conformation- and sequence-specific antibodies against amyloid β

  2011cited by this paper
• Drosophila models of Parkinson's disease.

  2011cited by this paper
• Designed hairpin peptides interfere with amyloidogenesis pathways: fibril formation and cytotoxicity inhibition, interception of the preamyloid state.

  2011cited by this paper
• Dynamic modeling of α-synuclein aggregation in dopaminergic neuronal system indicates points of neuroprotective intervention: experimental validation with implications for Parkinson's therapy.

  2011cited by this paper
• α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation

  2011cited by this paper
• Comparative Analysis of Different Peptidyl-Prolyl Isomerases Reveals FK506-binding Protein 12 as the Most Potent Enhancer of α-Synuclein Aggregation*

  2011cited by this paper
• Passive Immunization Reduces Behavioral and Neuropathological Deficits in an Alpha-Synuclein Transgenic Model of Lewy Body Disease

  2011cited by this paper
• Mechanism of membrane interaction and disruption by α-synuclein.

  2011cited by this paper
• Toward the Discovery of Effective Polycyclic Inhibitors of α-Synuclein Amyloid Assembly*

  2011cited by this paper
• Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies.

  2011cited by this paper
• Intrinsically disordered proteins from A to Z.

  2011cited by this paper
• Inhibition of FK506 Binding Proteins Reduces α-Synuclein Aggregation and Parkinson's Disease-Like Pathology

  2010cited by this paper
• The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia

  2010cited by this paper
• Membrane Permeabilization by Oligomeric α-Synuclein: In Search of the Mechanism

  2010cited by this paper
• The conformation and the aggregation kinetics of α-synuclein depend on the proline residues in its C-terminal region.

  2010cited by this paper
• A stable proportion of Lewy body bearing neurons in the substantia nigra suggests a model in which the Lewy body causes neuronal death.

  2010cited by this paper
• α-Synuclein Promotes SNARE-Complex Assembly in Vivo and in Vitro

  2010cited by this paper
• Inhibiting α-Synuclein Oligomerization by Stable Cell-Penetrating β-Synuclein Fragments Recovers Phenotype of Parkinson's Disease Model Flies

  2010cited by this paper
• EGCG remodels mature α-synuclein and amyloid-β fibrils and reduces cellular toxicity

  2010cited by this paper
• α-Synuclein and dopamine at the crossroads of Parkinson's disease.

  2010cited by this paper
• Drosophila Models of Parkinson’s Disease

  2010cited by this paper
• The regulation of synaptic function by α-synuclein

  2010cited by this paper
• Effects of curvature and composition on α-synuclein binding to lipid vesicles.

  2010cited by this paper
• Membrane Curvature Induction and Tubulation Are Common Features of Synucleins and Apolipoproteins*

  2010cited by this paper
• The regulation of synaptic function by alpha-synuclein.

  2010cited by this paper
• Brain-Permeable Small-Molecule Inhibitors of Hsp90 Prevent α-Synuclein Oligomer Formation and Rescue α-Synuclein-Induced Toxicity

  2010cited by this paper
• Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein

  2009cited by this paper
• Aggregation-defective alpha-synuclein mutants inhibit the fibrillation of Parkinson's disease-linked alpha-synuclein variants.

  2009cited by this paper
• Charge neutralization and collapse of the C‐terminal tail of alpha‐synuclein at low pH

  2009cited by this paper
• E46K Parkinson's-linked mutation enhances C-terminal-to-N-terminal contacts in alpha-synuclein.

  2009cited by this paper
• Curvature dynamics of alpha-synuclein familial Parkinson disease mutants: molecular simulations of the micelle- and bilayer-bound forms.

  2009cited by this paper
• An Analytical Solution to the Kinetics of Breakable Filament Assembly

  2009cited by this paper
• Pre‐fibrillar α‐synuclein variants with impaired β‐structure increase neurotoxicity in Parkinson's disease models

  2009cited by this paper
• Lewy body–like pathology in long-term embryonic nigral transplants in Parkinson's disease

  2008cited by this paper
• Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation

  2008cited by this paper
• Site-specific interactions of Cu(II) with alpha and beta-synuclein: bridging the molecular gap between metal binding and aggregation.

  2008cited by this paper
• The therapeutical potential of alpha-synuclein antiaggregatory agents for dementia with Lewy bodies.

  2008cited by this paper
• Single Particle Characterization of Iron-induced Pore-forming α-Synuclein Oligomers*

  2008cited by this paper
• Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years

  2008cited by this paper
• Non-invasive imaging of neuropathology in a rat model of alpha-synuclein overexpression.

  2007cited by this paper
• Pesticide exposure exacerbates alpha-synucleinopathy in an A53T transgenic mouse model.

  2007cited by this paper
• Mechanistic aspects of Parkinson’s disease: α-synuclein and the biomembrane

  2007cited by this paper
• Mechanistic aspects of Parkinson's disease: alpha-synuclein and the biomembrane.

  2007cited by this paper
• Alpha-Synuclein Misfolding and Aggregation in Parkinson's Disease

  2007cited by this paper
• Predominant neuritic pathology induced by viral overexpression of alpha-synuclein in cell culture.

  2007cited by this paper
• Predominant Neuritic Pathology Induced by Viral Overexpression of α-Synuclein in Cell Culture

  2007cited by this paper
• Pesticide Exposure Exacerbates α-Synucleinopathy in an A53T Transgenic Mouse Model

  2007cited by this paper
• α-Synuclein Overexpression in PC12 and Chromaffin Cells Impairs Catecholamine Release by Interfering with a Late Step in Exocytosis

  2006cited by this paper
• α-Synuclein Blocks ER-Golgi Traffic and Rab1 Rescues Neuron Loss in Parkinson's Models

  2006cited by this paper
• Interaction of alpha-synuclein with divalent metal ions reveals key differences: a link between structure, binding specificity and fibrillation enhancement.

  2006cited by this paper
• Alpha‐synuclein inhibits aromatic amino acid decarboxylase activity in dopaminergic cells

  2006cited by this paper
• Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease.

  2006cited by this paper
• The aggregation of alpha‐synuclein is stimulated by FK506 binding proteins as shown by fluorescence correlation spectroscopy

  2006cited by this paper
• Alpha-synuclein is upregulated in neurones in response to chronic oxidative stress and is associated with neuroprotection.

  2006cited by this paper
• Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration.

  2005cited by this paper
• Release of long-range tertiary interactions potentiates aggregation of natively unstructured alpha-synuclein.

  2005cited by this paper
• α-Synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells

  2005cited by this paper
• α-Synuclein Cooperates with CSPα in Preventing Neurodegeneration

  2005cited by this paper
• Locomotor activity and evoked dopamine release are reduced in mice overexpressing A30P-mutated human alpha-synuclein.

  2005cited by this paper
• Mapping long-range interactions in alpha-synuclein using spin-label NMR and ensemble molecular dynamics simulations.

  2005cited by this paper
• The E46K mutation in alpha-synuclein increases amyloid fibril formation.

  2005cited by this paper
• The E46K Mutation in α-Synuclein Increases Amyloid Fibril Formation*

  2005cited by this paper
• An antiaggregation gene therapy strategy for Lewy body disease utilizing β-synuclein lentivirus in a transgenic model

  2004cited by this paper
• Impact of the acidic C-terminal region comprising amino acids 109-140 on alpha-synuclein aggregation in vitro.

  2004cited by this paper
• Staging of brain pathology related to sporadic Parkinson's disease.

  2003cited by this paper

• Impairment in stimulus-response learning as a cognitive biomarker in a model of synucleinopathy

  2026cites this paper
• Disulfide engineering reveals unexpected pro- and anti-aggregation conformers of human α-synuclein

  2026cites this paper
• Small molecule inhibitors targeting alpha-synuclein aggregation: Progress and future outlook.

  2025cites this paper
• Microfluidic platform for understanding Parkinson’s disease and α-synuclein conformation

  2025cites this paper
• Diosgenin reduces β-sheet content in mutated α-syn aggregation: Insights from conformational dynamics at intracellular and extracellular neuronal salt concentrations.

  2025cites this paper
• Therapeutic potential of Coumarin-polyphenolic acid hybrids in PD: inhibition of α-Syn aggregation and disaggregation of preformed fibrils, leading to reduced neuronal inclusion formation.

  2024cites this paper
• Pyrazolamide derivatives inhibit α-Synuclein aggregation, disaggregate preformed fibers, and reduce inclusion formation in neuron cells.

  2024cites this paper
• Self-Blinking Thioflavin T for Super-resolution Imaging

  2024cites this paper
• Dopaminergic neuron loss in mice due to increased levels of wild-type human α-Synuclein only takes place under conditions of accelerated aging

  2024cites this paper
• A Plant Model of α-Synucleinopathy: Expression of α-Synuclein A53T Variant in Hairy Root Cultures Leads to Proteostatic Stress and Dysregulation of Iron Metabolism

  2024cites this paper
• In vitro inhibition of α-Synuclein aggregation and disaggregation of preformed fibers by polyphenol hybrids with 2-conjugated benzothiazole.

  2024cites this paper
• Posttranslational Modifications of α-Synuclein, Their Therapeutic Potential, and Crosstalk in Health and Neurodegenerative Diseases

  2024cites this paper
• Hybrids of polyphenolic/quinone acids, the potential preventive and therapeutic drugs for PD: Disaggregate α-Syn fibrils, inhibit inclusions, and repair damaged neurons in mice.

  2023cites this paper
• The potential of Rhein's aromatic amines for Parkinson's disease prevention and treatment: α-Synuclein aggregation inhibition and disaggregation of preformed fibers.

  2023cites this paper
• The Role of α-Synuclein in the Regulation of Serotonin System: Physiological and Pathological Features

  2023cites this paper
• Bis-chalcone polyphenols with potential preventive and therapeutic effects on PD: Design, synthesis and in vitro disaggregation activity against α-synuclein oligomers and fibrils.

  2022cites this paper
• UNEXPECTED PLASTICITY OF THE QUATERNARY STRUCTURE OF IRON-MANGANESE SUPEROXIDE DISMUTASES.

  2022cites this paper
• Hybrids of polyphenolic acids and xanthone, the potential preventive and therapeutic effects on PD: Design, synthesis, in vitro anti-aggregation of α-synuclein, and disaggregation against the existed α-synuclein oligomer and fibril.

  2022cites this paper
• Etiology and pathogenesis of Parkinson disease

  2021cites this paper
• Investigation of Inhibition Effect of Nicotine and Dopamine on Alpha-synuclein

  2021cites this paper
• Aptamers for the Diagnosis and Therapy of Neurodegenerative Diseases

  2021cites this paper
• Examining the Toxicity of α-Synuclein in Neurodegenerative Disorders

  2021cites this paper
• The Functions of Thioredoxin 1 in Neurodegeneration

  2021cites this paper
• The Non-Fibrillating N-Terminal of α-Synuclein Binds and Co-Fibrillates with Heparin

  2020cites this paper
• Modeling Parkinson’s Disease With the Alpha-Synuclein Protein

  2020cites this paper
• Overexpression of alpha-synuclein promotes both cell proliferation and cell toxicity in human SH-SY5Y neuroblastoma cells

  2020cites this paper
• Discerning Dynamic Signatures of Membrane-Bound α-Synuclein Using Site-Specific Fluorescence Depolarization Kinetics.

  2020cites this paper
• The Non-amyloidal Component Region of α-Synuclein Is Important for α-Synuclein Transport Within Axons

  2020cites this paper
• Behavioral Deficits and Brain α-Synuclein and Phosphorylated Serine-129 α-Synuclein in Male and Female Mice Overexpressing Human α-Synuclein

  2020cites this paper
• MMP13 Expression Is Increased Following Mutant α-Synuclein Exposure and Promotes Inflammatory Responses in Microglia

  2020cites this paper
• Alpha-Synuclein in the Gastrointestinal Tract as a Potential Biomarker for Early Detection of Parkinson’s Disease

  2020cites this paper
• An Adhesive Peptide from the C-Terminal Domain of α-Synuclein for Single-Layer Adsorption of Nanoparticles onto Substrates.

  2020cites this paper
• Neuroinflammation and Alpha-Synuclein Oligomer Toxicity in the Pathogenesis of Lewy Body Dementia and Parkinson's Disease

  2020influential citation
• Mesenchymal stem cells modulate misfolded α-synuclein in parkinsonian disorders: A multitarget disease-modifying strategy.

  2020cites this paper
• Computational Study on the Role of γ-Synuclein in Inhibiting the α-Synuclein Aggregation.

  2019cites this paper
• Insight into the molecular mechanism underlying the inhibition of α-synuclein aggregation by hydroxytyrosol.

  2019cites this paper
• Is modulation of glucocerebrosidase a viable new treatment for Parkinson's disease?

  2019cites this paper
• Two C-terminal sequence variations determine differential neurotoxicity between human and mouse α-synuclein

  2019cites this paper
• Anti-oligomerization sheet molecules: Design, synthesis and evaluation of inhibitory activities against α-synuclein aggregation.

  2019cites this paper
• Living in Promiscuity: The Multiple Partners of Alpha-Synuclein at the Synapse in Physiology and Pathology

  2019cites this paper
• Toll-Like Receptor 2 Signaling and Current Approaches for Therapeutic Modulation in Synucleinopathies

  2018cites this paper
• Electrostatic and hydrophobic interactions of lipid-associated α-synuclein: The role of a water-limited interfaces in amyloid fibrillation.

  2018cites this paper
• Insights into the Molecular Mechanisms of Alzheimer’s and Parkinson’s Diseases with Molecular Simulations: Understanding the Roles of Artificial and Pathological Missense Mutations in Intrinsically Disordered Proteins Related to Pathology

  2018cites this paper
• Synergistic Amyloid Switch Triggered by Early Heterotypic Oligomerization of Intrinsically Disordered α-Synuclein and Tau.

  2018cites this paper
• Toxic properties of microsome-associated alpha-synuclein species in mouse primary neurons.

  2018cites this paper
• Formation of Heterotypic Amyloids: α‐Synuclein in Co‐Aggregation

  2018cites this paper
• Gut and Parkinson’s disease

  2018cites this paper
• The Impact of Methylenetetrahydrofolate Reductase (MTHFR) Deficiency in a Paraquat Mouse Model of Parkinson’s Disease

  2018cites this paper
• Effects of Alpha-Synuclein on Primary Spinal Cord Neurons Associated with Apoptosis and CNTF Expression

  2017cites this paper
• The gut-brain axis: is intestinal inflammation a silent driver of Parkinson’s disease pathogenesis?

  2017cites this paper
• Aggregation of alpha-synuclein using single-molecule spectroscopy

  2017cites this paper
• Implications of peptide assemblies in amyloid diseases.

  2017cites this paper
• Potential of mean force and molecular dynamics study on the transient interactions between α and β synuclein that drive inhibition of α-synuclein aggregation

  2017cites this paper
• α‐Synuclein Oligomers: A Study in Diversity

  2017cites this paper
• Prospective of SNCA in nervous system diseases

  2017cites this paper
• Structural characterization of the interaction of α-synuclein nascent chains with the ribosomal surface and trigger factor

  2016cites this paper
• Aptamer and its applications in neurodegenerative diseases

  2016cites this paper
• Isoliquiritigenin and liquiritin from Glycyrrhiza uralensis inhibit α-synuclein amyloid formation

  2016cites this paper
• Coupling of the non-amyloid-component (NAC) domain and the KTK(E/Q)GV repeats stabilize the α-synuclein fibrils.

  2016cites this paper
• High-content analysis of α-synuclein aggregation and cell death in a cellular model of Parkinson's disease.

  2016cites this paper
• Rôle de Lmx1a et de Lmx1b dans la maintenance des circuits dopaminergiques chez la souris adulte

  2015cites this paper
• igh-content analysis of-synuclein aggregation and cell death in a ellular model of Parkinson ’ s disease

  2015cites this paper
• Polyphenols neuroprotective effect in a Parkinson’s disease yeast model: phosphoproteome alterations

  2015cites this paper
• Control of protein orientation on gold nanoparticles.

  2015cites this paper
• Promising Targets for the Treatment of Neurodegenerative Diseases

  2015cites this paper
• Direct Detection of α-Synuclein Dimerization Dynamics: Single-Molecule Fluorescence Analysis.

  2015cites this paper
• Insight into conformational modification of alpha‐synuclein in the presence of neuronal whole cells and of their isolated membranes

  2015cites this paper
• Malleable nature of mRNA-protein compositional complementarity and its functional significance

  2015cites this paper
• Nigral overexpression of alpha-synuclein in the absence of parkin enhances alpha-synuclein phosphorylation but does not modulate dopaminergic neurodegeneration

  2015cites this paper
• Features of alpha-synuclein that could explain the progression and irreversibility of Parkinson's disease

  2015cites this paper
• Alpha-synuclein Toxicity in the Early Secretory Pathway: How It Drives Neurodegeneration in Parkinsons Disease

  2015influential citation
• α-Synuclein and Lewy pathology in Parkinson's disease.

  2015cites this paper
• Hot, Hotter, and Hottest Trends in α-Synuclein Research.

  2015cites this paper
• Activation of Mitochondrial Complex II-Dependent Respiration Is Beneficial for α-Synucleinopathies

  2015cites this paper
• Site-specific fluorescence dynamics of α-synuclein fibrils using time-resolved fluorescence studies: effect of familial Parkinson's disease-associated mutations.

  2014cites this paper
• Naturally Occurring Alpha-Synuclein Autoantibodies in Parkinson’s Disease: Sources of (Error) Variance in Biomarker Assays

  2014cites this paper
• Transient dynamics of Aβ contribute to toxicity in Alzheimer’s disease

  2014cites this paper
• Identification of Atg3 as an intrinsically disordered polypeptide yields insights into the molecular dynamics of autophagy-related proteins in yeast

  2014cites this paper
• Models of α-synuclein aggregation in Parkinson’s disease

  2014influential citation
• Polyphenols neuroprotective effect in a Parkinson ’ s disease yeast model : phosphoproteome alterations

  2014cites this paper
• Correlation between the biochemical pathways altered by mutated parkinson-related genes and chronic exposure to manganese.

  2014cites this paper
• In vitro aggregation assays for the characterization of α-synuclein prion-like properties

  2014cites this paper
• Neurodegenerative aspects of multiple system atrophy

  2014cites this paper
• Influence of the polypeptide environment next to amyloidogenic peptides on fibril formation

  2014cites this paper
• The triple power of D³: protein intrinsic disorder in degenerative diseases.

  2014cites this paper
• The crowd you're in with: effects of different types of crowding agents on protein aggregation.

  2014cites this paper
• Ceftriaxone blocks the polymerization of α-synuclein and exerts neuroprotective effects in vitro.

  2014cites this paper
• Noninvasive Bioluminescence Imaging of α-Synuclein Oligomerization in Mouse Brain Using Split Firefly Luciferase Reporters

  2014cites this paper
• Structural and Dynamical Insights into the Membrane-Bound α-Synuclein

  2013cites this paper
• Digested disorder

  2013cites this paper
• Biophysical characterization of α-synuclein and its controversial structure

  2013cites this paper
• Two C-terminal Sequence Variations Determine Differential Two C-terminal Sequence Variations Determine Differential Neurotoxicity Between Human and Mouse α -synuclein Neurotoxicity Between Human and Mouse -synuclein

  year unknowncites this paper